US FDA Commissioner Stephen Hahn acknowledged in a 16 April statement that the strain the agency is feeling from its coronavirus response could cause it to miss some of its user fee deadlines.
“At this time, the New Drug Program, the Generic Drug Program, and the Biologics and Biosimilars Programs are continuing to...








